6533b7d2fe1ef96bd125e2a7

RESEARCH PRODUCT

Constitutive activation of JAK2 in mammary epithelium elevates Stat5 signalling, promotes alveologenesis and resistance to cell death, and contributes to tumourigenesis

Rosa ZaragozaRosa ZaragozaSara PensaMaría M. CaffarelJuan LiChristine J. WatsonAnthony R. Green

subject

MaleMammary glandTransplantation HeterologousMutation MissenseMice NudeBreast NeoplasmsMammary Neoplasms AnimalMiceMammary Glands AnimalPregnancyhemic and lymphatic diseasesCell Line TumormedicineSTAT5 Transcription FactorAnimalsHumansLactationSTAT3Mammary Glands HumanMolecular BiologySTAT5Mice KnockoutOriginal PaperJanus kinase 2biologyCell DeathCell growthCell BiologyJanus Kinase 2Enzyme Activationmedicine.anatomical_structureCell Transformation Neoplasticbiology.proteinSTAT proteinCancer researchFemaleSignal transductionJanus kinaseNeoplasm TransplantationSignal Transduction

description

Signalling through the janus kinase (JAK)/signal transducer and activator of transcription (Stat) pathway is required at different stages of mammary gland development, and this pathway is frequently hyper-activated in cancer, including tumours of the breast. Stats 3, 5 and 6 have important roles in the differentiation and survival of mammary alveolar cells, but somewhat paradoxically, both Stat3 and 5 can have oncogenic activity in the mammary gland. Constitutive activation of JAK2 could be anticipated to result in hyper-activation of Stats 1, 3, 5 and 6 with concomitant cell transformation, although the outcome is difficult to envisage, particularly since Stats 3 and 5 play opposing roles in normal mammary gland development. Here, we show that expression of a constitutively active JAK2 mutant, JAK2 V617F, leads to hyper-activation of Stat5 in mammary epithelial cells (MECs), and transgenic mice expressing JAK2 V617F specifically in the mammary gland exhibit accelerated alveologenesis during pregnancy and delayed post-lactational regression. Overexpressing JAK2 V617F in MECs in vitro results in elevated proliferation and resistance to cell death. Furthermore, constitutively active JAK2 enhances anchorage-independent cell growth in the presence of a co-operating oncogene and accelerates tumourigenesis in a xenograft model. Taken together, our results provide insights into signalling downstream of constitutively active JAK2 and could be important for understanding the molecular mechanisms of breast tumourigenesis.

10.1038/cdd.2011.122https://europepmc.org/articles/PMC3272416/